AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 141 min read$VYX

NCR Voyix Corporation (VYX) Wins Multi-Year Sbarro Platform Deal

NCR Voyix (VYX) secured a multi-year deal with Sbarro to deploy its Aloha Next POS and Voyix Pay systems across 300 U.S. locations. The agreement aims to unify in-store and above-store operations, extending their existing partnership. Investors should monitor deployment timelines and financial impacts.

Original reporting
tradingview.com
Published Oct 14, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 12:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
NCR Voyix Corporation (VYX) Wins Multi-Year Sbarro Platform Deal — source image
Source · tradingview.com
Decision brief

The 30-second read

$VYXBullishLow
01

Why it matters

The Sbarro contract expands Voyix's footprint and could improve its top-line growth, but the scale is modest.

02

Market read

A new multi-year restaurant POS contract for a small-cap tech firm; modest trading relevance.

03

What to watch

Execution risk and integration timeline could delay revenue benefits.

Relevance 5/10Novelty 5/10Timing: today

Background

NCR Voyix is a provider of point-of-sale and payment solutions targeting the restaurant industry.

Company-level read

Ticker impact

$VYXBullishMedium confidence
Context

NCR Voyix announced a multi-year agreement with Sbarro to deploy its POS and payment platform across ~300 locations.

Expected impact

likely modest upside as investors price in the new restaurant platform deal

Evidence & confidence

New multi-year deal adds incremental revenue; impact size is limited given the company's small scale.

Market effects

Sector

May signal continued growth in restaurant POS and payment solutions.

Regional

U.S. restaurant technology market sees incremental demand.

Global

Limited to niche POS sector.

Counterpoint

What could challenge this read

Deal size may be too small to move the stock significantly; investors could be overestimating impact.

Key entities

  • Company
    NCR Voyix Corporation

    Provider of POS and payment platforms for restaurants.

  • Company
    Sbarro

    U.S. pizza restaurant chain.

Read at source← All news

Related articles

AUG 9
$VYXMed

NCR Voyix Q2 Earnings Call Highlights

NCR Voyix (NYSE:VYX) reported Q2 progress on enterprise platform transformations, including a remote Voyix POS installation for a large European grocery retailer completed in about half the usual time. Retail signed 40+ customers; retail revenue fell 20% to $365M due to hardware transition, but adjusted EBITDA rose 20% to $97M. Restaurant revenue fell 23% to $158M. Non-GAAP EPS was $0.17. Full-year 2026 outlook maintained: revenue $2.188B-$2.303B, adj EBITDA $432M-$447M, EPS $0.89-$0.92.

yahoo.com6 min
AUG 5
$VYXMedAI 8/10

NCR Voyix: Q2 Earnings Snapshot

NCR Voyix (VYX) reported Q2 earnings of $2 million and a net loss of 1 cent per share. Adjusted earnings were 17 cents per share, and revenue was $523 million. The company expects full-year earnings of 89 to 92 cents per share and revenue of $2.19 billion to $2.3 billion.

local3news.com2 min
AUG 5
$VYXMed

NCR Voyix Corp (VYX): Completion of Acquisition or Disposition of Assets

NCR Voyix Corp (VYX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. NEWS RELEASE NCR Voyix Reports Second Quarter 2026 Results ATLANTA, August 5, 2026 - NCR Voyix Corporation (NYSE: VYX) (“NCR Voyix” or the “Company”), a platform-powered leader in unified commerce for shopping and dining, reported financial results today for the three and six mon

SEC EDGAR 8-K4 min
OCT 25
$AMRNMedAI 8/10

Amarin’s icosapent ethyl shows survival benefit in cancer trial

Amarin Corporation (NASDAQ:AMRN) reported Phase 3 trial results for icosapent ethyl in colorectal cancer liver metastases. The primary endpoint of progression-free survival was not met, but the key secondary endpoint of overall survival showed a statistically significant benefit. The five-year overall survival estimate was 62.0% with icosapent ethyl versus 45.1% with placebo. The drug was found to be safe and well tolerated.

investing.com2 min
OCT 25
$AMRNMedAI 8/10

A colorectal cancer trial missed its goal, but estimated 5-year survival was 62% with the drug versus 45% with placebo.

Amarin's drug VASCEPA failed to meet its primary endpoint in a colorectal cancer trial but showed a 5-year survival rate of 62% vs. 45% with placebo. The study, sponsored by the University of Leeds, found improved overall survival but not progression-free survival. Amarin plans further evaluation, citing potential long-term value.

stocktitan.net2 min